Efficacy and safety of different proprotein convertase subtilisin/kexin type 9 inhibitors in the general population and solid organ transplant recipients: a network meta-analysis
Evolocumab is optimal for LDL-C and CVE reduction, while Ongericimab and Alirocumab offer better safety profiles. PCSK9 inhibitors did not increase acute rejection or infection risk in SOT recipients. Long-term mortality benefits remain uncertain.
Authors
- Zhuang Sun (ORCID: https://orcid.org/0000-0002-5159-3753)
- Han Luo (ORCID: https://orcid.org/0000-0002-2209-7443)
- Bohan Luo
Institutions
- University of Electronic Science and Technology of China (CN)
- Chinese Academy of Sciences (CN)
- Zigong First People's Hospital (CN)
- Ningbo Institute of Industrial Technology (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-08-22
- DOI
- https://doi.org/10.3389/fphar.2025.1584612
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 0.00